MedPath

Measurement of plasma beta-amyloid levels after glucose loading as diagnostic biomarker for Alzheimer disease

Not Applicable
Conditions
Alzheimer&#39
s disease
Registration Number
JPRN-UMIN000004895
Lead Sponsor
Osaka University
Brief Summary

The plasma levels of baseline blood glucose, plasma insulin, and plasma Abeta were not different between the two groups. However, immediately after glucose loading, a significant increase in plasma Abeta40 and Abeta42 levels was observed in AD patients, whereas a mild decrease in plasma Abeta40 and Abeta42 levels was detected in non-AD dementia patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
21
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with diabetes mellitus

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Plasma beta amyloid levels after glucose loading
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath